双示踪剂PET/CT对接受177Lu-PSMA放射性配体治疗患者的预后意义
该双中心分析纳入54例转移性去势抵抗性前列腺癌患者,在177Lu-PSMA放射性配体治疗前进行FDG与PSMA配体PET/CT显像。存在至少一个FDG阳性/PSMA阴性病灶的患者中位总生存期显著低于无此类病灶者(6.0个月 vs 16.0个月,p<0.001)。FDG阳性/PSMA阴性病灶是总生存期的负面预测因子。
要点
- FDG阳性/PSMA阴性病灶是mCRPC患者接受PSMA RLT后总生存期的负面预测因子。
- 基线存在FDG阳性/PSMA阴性病灶者中位OS为6.0个月,无此类病灶者为16.0个月。
- 是否应将存在FDG阳性/PSMA阴性病灶的患者排除于PSMA RLT之外尚待确定。
核心结论
- FDG阳性/PSMA阴性病灶是接受RLT的mCRPC患者总生存期的负面预测因子。
- 存在FDG阳性/PSMA阴性病灶的患者是否应被排除于PSMA RLT之外仍需进一步确定。
研究设计与样本
- 双中心分析纳入54例转移性去势抵抗性前列腺癌患者,均在RLT前接受FDG与PSMA配体PET/CT显像。
- 对所有患者的PSMA配体与FDG摄取模式进行视觉评估。
- 将至少有一个FDG阳性但PSMA阴性病灶的患者与无任何FDG阳性/PSMA阴性病灶的患者进行比较。
- 采用log-rank分析评估亚组间总生存期的差异。
主要发现
- 中位总生存期为11 ± 1.8个月(95% CI 7.4-14.6)。
- 基线PET/CT存在至少一个FDG阳性/PSMA阴性病灶的患者(n=18)中位OS为6.0 ± 0.5个月(95% CI 5.0-7.0),显著更低(p < 0.001)。
- 无任何FDG阳性/PSMA阴性病灶的患者(n=36)中位OS为16.0 ± 2.5个月(95% CI 11.2-20.8)。
关键数值与推荐
- FDG阳性/PSMA阴性病灶定义为至少一个FDG阳性但PSMA阴性的病灶。
- 存在至少一个FDG阳性/PSMA阴性病灶者中位OS为6.0 ± 0.5个月(95% CI 5.0-7.0)。
- 无任何FDG阳性/PSMA阴性病灶者中位OS为16.0 ± 2.5个月(95% CI 11.2-20.8)。
- 两组OS差异的p值小于0.001。
临床怎么用
- 对拟接受177Lu-PSMA RLT的mCRPC患者,治疗前可考虑联合PSMA配体与FDG PET/CT显像以识别FDG阳性/PSMA阴性病灶。
- FDG阳性/PSMA阴性病灶的存在提示总生存期较差,可用于预后分层。
局限性
- FDG阳性/PSMA阴性病灶患者是否应排除于PSMA RLT之外尚待确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) with 177Lu-labeled PSMA ligands has achieved remarkable results in advanced disease stages of metastatic castration-resistant prostate cancer (mCRPC). However, not all patients benefit from this therapy. Different treatment responses could be explained by tumor heterogeneity triggered by progression and the number of prior treatments. PSMA-negative lesions can be missed on PSMA ligand PET/CT, which subsequently results in an underestimation of tumor burden. Conversely, high FDG uptake may also be an indicator of tumor aggressiveness and thus a poor prognostic marker for response to RLT and overall survival (OS). The aim of this analysis was to investigate the prognostic value of combined PSMA ligand PET/CT and [18F]fluorodeoxyglucose (FDG) PET/CT for outcome prediction in patients undergoing RLT. MATERIALS AND METHODS: This bicentric analysis included 54 patients with mCRPC who underwent both FDG and PSMA ligand PET/CT imaging before RLT. In all patients, the pattern of PSMA ligand and FDG uptake was visually assessed. Patients with at least one FDG-positive, but PSMA-negative (FDG+/PSMA-) lesions were compared to patients without any FDG+/PSMA- lesions. A log-rank analysis was used to assess the difference in OS between subgroups. RESULTS: Median OS was 11 ± 1.8 months (95% CI 7.4-14.6). A significantly lower OS (p < 0.001) was found in patients with at least one FDG+/PSMA- lesion at baseline PET/CTs (n = 18) with a median OS of 6.0 ± 0.5 months (95% CI: 5.0-7.0 months). In comparison, patients without any FDG+/PSMA- lesions (n = 36) had a median OS of 16.0 ± 2.5 months (95% CI: 11.2-20.8 months). CONCLUSION: FDG+/PSMA- lesions are a negative predictor of overall survival in patients with mCRPC undergoing RLT. However, it remains to be determined if patients with FDG+/PSMA- lesions should be excluded from PSMA RLT.
引用
- Michalski K, Ruf J, Goetz C, et al. Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy. Eur J Nucl Med Mol Imaging. 2020. PMID: 33336265. doi:10.1007/s00259-020-05160-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。